Evidence map›Paper›PMID 39518392›Full record

ArticleDiagnostics (Basel, Switzerland)2024

A Retrospective Cohort Study of a Newly Proposed Criteria for Sporadic Creutzfeldt-Jakob Disease.

Toshiaki Nonaka, Ryusuke Ae, Koki Kosami, Hiroya Tange, Miho Kaneko, Takehiro Nakagaki, Tsuyoshi Hamaguchi, Nobuo Sanjo, Yoshikazu Nakamura, Tetsuyuki Kitamoto and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Toshiaki NonakaDepartment of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.ORCID 0009-0001-9914-2599
Ryusuke AeJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0003-2660-530X
Koki KosamiJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0003-1050-2699
Hiroya TangeDepartment of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.
Miho KanekoDepartment of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.
Takehiro NakagakiDepartment of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.ORCID 0000-0003-1960-8326
Tsuyoshi HamaguchiJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Nobuo SanjoJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Yoshikazu NakamuraJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0001-6654-1481
Tetsuyuki KitamotoJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Yoshiyuki KuroiwaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Kensaku KasugaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0002-2178-0769
Manabu DoyuJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0002-6264-9927
Fumiaki TanakaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Koji AbeJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Shigeo MurayamaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Ichiro YabeJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0002-1734-7997
Hideki MochizukiJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Takuya MatsushitaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0002-4629-1312
Hiroyuki MuraiJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Masashi AokiJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Koji FujitaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Masafumi HaradaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Masaki TakaoJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Tadashi TsukamotoJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Yasushi IwasakiDepartment of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute 480-1195, Japan.ORCID 0000-0002-0059-3104
Masahito YamadaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0003-2416-5662
Hidehiro MizusawaJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.
Katsuya SatohJapanese Prion Disease Surveillance Committee, Tokyo 187-8551, Japan.ORCID 0000-0001-8007-8710
Noriyuki NishidaDepartment of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan.

Funding

AMED JP23ek0109620Research Committee of Prion Disease and Slow Virus Infection, Ministry of Health, Labour, Welfare 23FC1007Research Committee on Surveillance and Infection Control of Prion Disease, Ministry of Health, Labour, Welfare 22FC2002
6 · The paper itself

Abstract

BACKGROUND/

objectivesSporadic Creutzfeldt-Jakob disease (sCJD) is a fatal neurodegenerative disorder traditionally diagnosed based on the World Health Organization (WHO) criteria in 1998. Recently, Hermann et al. proposed updated diagnostic criteria incorporating advanced biomarkers to enhance early detection of sCJD. This study aimed to evaluate the sensitivity and specificity of Hermann's criteria compared with those of the WHO criteria in a large cohort of patients suspected of prion disease in Japan.

methodsIn this retrospective cohort study, we examined the new criteria using data of 2004 patients with suspected prion disease registered with the Japanese Prion Disease Surveillance (JPDS) between January 2009 and May 2023. Patients with genetic or acquired prion diseases or incomplete data necessary for the diagnostic criteria were excluded, resulting in 786 eligible cases. The sensitivity and specificity of the WHO and Hermann's criteria were calculated by comparing diagnoses with those made by the JPDS Committee.

resultsOf the 786 included cases, Hermann's criteria helped identify 572 probable cases compared with 448 by the WHO criteria. The sensitivity and specificity of the WHO criteria were 96.4% and 96.6%, respectively. Hermann's criteria demonstrated a sensitivity of 99.3% and a specificity of 95.2%, indicating higher sensitivity but slightly lower specificity. Fifty-five cases were classified as "definite" by both criteria.

conclusionsThe findings suggest that Hermann's criteria could offer improved sensitivity for detecting sCJD, potentially reducing diagnostic oversight. However, caution is advised in clinical practice to avoid misdiagnosis, particularly in treatable neurological diseases, by ensuring thorough exclusion of other potential conditions.

Indexed as

biomarkerdiagnostic criteriamagnetic resonance imagingprion diseasereal-time quaking-induced conversionsporadic Creutzfeldt–Jakob disease

Identifiers

PMID39518392
PMCPMC11545003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.